IL17A and psoriasis: Moreover, as a critical intracellular kinase within this pathway, tyrosine kinase 2 mediates IL-23 receptor signaling and downstream STAT3 activation, making it a promising therapeutic target for disrupting the IL-23/IL-17-driven inflammatory cascade in psoriasis [40].